Cytomegalovirus and Epstein-Barr virus infection during daratumumab treatment in patients with multiple myeloma

References

• Palumbo A, Anderson K. Multiple Myeloma. N Engl J Med. 2011;364(11):1046–1060.
   PubMed Web of Science ®Google Scholar
• Bazarbachi AH, Al Hamed R, Malard F, et al. Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia. 2019;33(10):2343–2357.
   PubMed Web of Science ®Google Scholar
• Sanchez L, Wang Y, Siegel DS, et al. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016;9(1):51.
   PubMedGoogle Scholar
• Piedra-Quintero ZL, Wilson Z, Nava P, et al. CD38: an immunomodulatory molecule in inflammation and autoimmunity. Front Immunol. 2020;11(597959)
   PubMedGoogle Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551–1560..
   PubMed Web of Science ®Google Scholar
• van de Donk NWCJ, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13–29.
   PubMed Web of Science ®Google Scholar
• Johnsrud A, Susanibar S, Jo Kamimoto J, et al. Infectious complications of daratumumab-containing therapy for multiple myeloma. Blood. 2017;130(Supplement 1):3148.
   Google Scholar
• Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518–528.
   PubMed Web of Science ®Google Scholar
• Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom medical research council trials between 1980 and 2002—medical research council adult leukaemia working party. J Clin Oncol. 2005;23(36):9219–9226.
   PubMed Web of Science ®Google Scholar
• Blimark C, Holmberg E, Mellqvist UH, et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica. 2015;100(1):107–113.
   PubMed Web of Science ®Google Scholar
• Li L, Wang L. Multiple myeloma: what do We do about immunodeficiency? J Cancer. 2019;10(7):1675–1684.
   PubMed Web of Science ®Google Scholar
• Ferreira LM, Cerezer JL, Gehrcke M. Do cytomegalovirus infections affect the daratumumab treatment course in multiple myeloma patients? – Literature review. Hematol Transfus Cell Ther. 2021;43(2):185–190.
   PubMedGoogle Scholar
• Frerichs KA, Bosman PWC, Nijhof IS, et al. Cytomegalovirus reactivation in a patient with extensively pretreated multiple myeloma during daratumumab treatment. Clin Lymphoma Myeloma Leuk. 2019;19(1):e9–e11.
   PubMed Web of Science ®Google Scholar
• Lee SK, Sung PS, Park SS, et al. Reactivation of resolved hepatitis B after daratumumab for multiple myeloma. Clin Infect Dis. 2021;73(6):e1372–e5.
   PubMed Web of Science ®Google Scholar
• Nakagawa R, Onishi Y, Kawajiri A, et al. Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma. Ann Hematol. 2019;98(8):1999–2001.
   PubMed Web of Science ®Google Scholar
• Facon T, Cook G, Usmani SZ, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36(4):1066–1077.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Chanan-Khan A, Weisel K, et al. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, Open-Label, phase III trial. J Clin Oncol. 2022; JCO2102734.
   Google Scholar
• Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582–1596.
   PubMed Web of Science ®Google Scholar
• Tabata R, Sato N, Yamauchi N, et al. Cytomegalovirus reactivation in patients with multiple myeloma administered daratumumab-combination regimens. 2022;101(2):467.
   Google Scholar
• Johnsrud AJ, Johnsrud JJ, Susanibar SA, et al. Infectious and immunological sequelae of daratumumab in multiple myeloma. Br J Haematol. 2019;185(1):187–189.
   PubMed Web of Science ®Google Scholar
• Casneuf T, Xu XS, Adams HC, 3rd, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2017;1(23):2105–2114.
   PubMed Web of Science ®Google Scholar
• Pierceall WE, Amatangelo MD, Bahlis NJ, et al. Immunomodulation in pomalidomide, dexamethasone, and daratumumab-treated patients with relapsed/refractory multiple myeloma. Clin Cancer Res. 2020;26(22):5895–5902.
   PubMed Web of Science ®Google Scholar
• Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384–394.
   PubMed Web of Science ®Google Scholar
• Sharpley FA, De‐Silva D, Mahmood S, et al. Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis. Eur J Haematol. 2020;104(3):230–235.
   PubMed Web of Science ®Google Scholar
• Marchesi F, Mengarelli A, Giannotti F, et al. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the rome transplant network. Transpl Infect Dis. 2014;16(1):158–164.
   PubMed Web of Science ®Google Scholar
• Jones RJ, Iempridee T, Wang X, et al. Lenalidomide, thalidomide, and pomalidomide reactivate the Epstein-Barr virus lytic cycle through phosphoinositide 3-Kinase signaling and ikaros expression. Clin Cancer Res. 2016;22(19):4901–4912.
   PubMed Web of Science ®Google Scholar
• Drgona L, Gudiol C, Lanini S, et al. ESCMID Study group for infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect. 2018;24(Suppl 2): S83–S94.
   PubMedGoogle Scholar
• Burns DM, Rana S, Martin E, et al. Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT. Bone Marrow Transplant. 2016;51(6):825–832.
   PubMed Web of Science ®Google Scholar
• Wei X, Xie Y, Jiang R, et al. The impact of rituximab administered before transplantation in patients undergoing allogeneic hematopoietic stem cell transplantation: a real-world study. Front Immunol. 2022;13:967026.
   PubMedGoogle Scholar
• Schachtner T, Reinke P. Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study. Transpl Infect Dis. 2016;18(6):881–888.
   PubMed Web of Science ®Google Scholar
• Worth A, Conyers R, Cohen J, et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol. 2011;155(3):377–385.
   PubMed Web of Science ®Google Scholar
• Ahmad I, Cau NV, Kwan J, et al. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation. 2009;87(8):1240–1245.
   PubMed Web of Science ®Google Scholar
• Coppoletta S, Tedone E, Galano B, et al. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(6):901–907.
   PubMed Web of Science ®Google Scholar
• Liu Q, Xuan L, Liu H, et al. Molecular monitoring and stepwise preemptive therapy for Epstein-Barr virus viremia after allogeneic stem cell transplantation. Am J Hematol. 2013;88(7):550–555.
   PubMed Web of Science ®Google Scholar
• Carpenter B, Haque T, Dimopoulou M, et al. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010;90(5):564–570.
   PubMed Web of Science ®Google Scholar
• van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood. 2002;99(12):4364–4369.
   PubMed Web of Science ®Google Scholar
• van der Velden WJ, Mori T, Stevens WB, et al. Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab. Bone Marrow Transplant. 2013;48(11):1465–1471.
   PubMed Web of Science ®Google Scholar
• Stocker N, Labopin M, Boussen I, et al. Pre-emptive rituximab treatment for Epstein-Barr virus reactivation after allogeneic hematopoietic stem cell transplantation is a worthwhile strategy in high-risk recipients: a comparative study for immune recovery and clinical outcomes. Bone Marrow Transplant. 2020;55(3):586–594.
   PubMed Web of Science ®Google Scholar
• Savoldo B, Rooney CM, Quiros-Tejeira RE, et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant. 2005;5(3):566–572.
   PubMed Web of Science ®Google Scholar
• Choquet S, Varnous S, Deback C, et al. Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation. Am J Transplant. 2014;14(4):857–866.
   PubMed Web of Science ®Google Scholar
• Walti LN, Mugglin C, Sidler D, et al. Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): a nationwide cohort study. Am J Transplant. 2021;21(7):2532–2542.
   PubMed Web of Science ®Google Scholar
• Martinez-Calle N, Alfonso A, Rifon J, et al. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-Centre study. Eur J Haematol. 2017;98(1):38–43.
   PubMed Web of Science ®Google Scholar
• Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol. 2013;162(3):376–382.
   PubMed Web of Science ®Google Scholar
• Meng G-Q, Wang J-S, Wang Y-N, et al. Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection. Int Immunopharmacol. 2021;96:107606.
   PubMed Web of Science ®Google Scholar
• Comoli P, Basso S, Zecca M, et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant. 2007;7(6):1648–1655.
   PubMed Web of Science ®Google Scholar
• Ohta K, Shimizu M, Nakai A, et al. Rituximab therapy for Epstein-Barr virus-related chronic hepatitis following living donor kidney transplantation. Am J Kidney Dis. 2006;48(6):986–989.
   PubMed Web of Science ®Google Scholar
• Cohen JI, Jaffe ES, Dale JK, et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011;117(22):5835–5849.
   PubMed Web of Science ®Google Scholar
• Styczynski J, van der Velden W, Fox CP, et al. Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: sixth european conference on infections in leukemia (ECIL-6) guidelines. Haematologica. 2016;101(7):803–811.
   PubMed Web of Science ®Google Scholar
• Roddie C, Peggs KS. Immunotherapy for transplantation-associated viral infections. J Clin Invest. 2017;127(7):2513–2522.
   PubMed Web of Science ®Google Scholar
• Yoshimori M, Shibayama H, Imadome KI, et al. Antineoplastic and anti-inflammatory effects of bortezomib on systemic chronic active EBV infection. Blood Adv. 2021;5(7):1805–1815.
   PubMed Web of Science ®Google Scholar
• Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–1238.
   PubMed Web of Science ®Google Scholar
• Ferrari V, Cacere CR, Machado CM, et al. Distinct patterns of regeneration of central memory, effector memory and effector TCD8+ cell subsets after different hematopoietic cell transplant types: possible influence in the recovery of anti-cytomegalovirus immune response and risk for its reactivation. Clin Immunol. 2006;119(3):261–271.
   PubMed Web of Science ®Google Scholar
• Czyzewski K, Dziedzic M, Salamonowicz M, et al. Epidemiology, outcome and risk factors analysis of viral infections in children and adolescents undergoing hematopoietic cell transplantation: antiviral drugs do not prevent Epstein-Barr virus reactivation. Infect Drug Resist. 2019;12:3893–3902.
   PubMed Web of Science ®Google Scholar
• Rossini F, Terruzzi E, Cammarota S, et al. Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program. Transpl Infect Dis. 2005;7(3–4):122–125.
   PubMed Web of Science ®Google Scholar
• Hussein AA, Al-Antary ET, Najjar R, et al. Incidence and risk factors for cytomegalovirus (CMV) reactivation following autologous hematopoietic stem cell transplantation in children. Pediatr Blood Cancer. 2015;62(6):1099–1101.
   PubMed Web of Science ®Google Scholar